Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.

Pineda JR, Pardo R, Zala D, Yu H, Humbert S, Saudou F.

Mol Brain. 2009 Oct 27;2:33. doi: 10.1186/1756-6606-2-33.

2.

Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421.

Pardo R, Colin E, Régulier E, Aebischer P, Déglon N, Humbert S, Saudou F.

J Neurosci. 2006 Feb 1;26(5):1635-45.

3.

[Huntington's disease: intracellular signaling pathways and neuronal death].

Humbert S, Saudou F.

J Soc Biol. 2005;199(3):247-51. Review. French.

PMID:
16471265
4.

Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.

Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F.

Hum Mol Genet. 2008 Dec 15;17(24):3837-46. doi: 10.1093/hmg/ddn281. Epub 2008 Sep 4.

PMID:
18772195
5.

Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.

Brito V, Puigdellívol M, Giralt A, del Toro D, Alberch J, Ginés S.

Cell Death Dis. 2013 Apr 18;4:e595. doi: 10.1038/cddis.2013.116.

6.

Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.

Xifró X, García-Martínez JM, Del Toro D, Alberch J, Pérez-Navarro E.

J Neurochem. 2008 Jun;105(5):1596-612. doi: 10.1111/j.1471-4159.2008.05252.x. Epub 2008 Jan 24.

7.

Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.

Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.

Hum Mol Genet. 2006 Jun 15;15(12):2015-24. Epub 2006 May 10.

PMID:
16687439
8.

Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.

Liot G, Zala D, Pla P, Mottet G, Piel M, Saudou F.

J Neurosci. 2013 Apr 10;33(15):6298-309. doi: 10.1523/JNEUROSCI.2033-12.2013.

9.

Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease.

Rué L, Alcalá-Vida R, López-Soop G, Creus-Muncunill J, Alberch J, Pérez-Navarro E.

Neuromolecular Med. 2014 Mar;16(1):25-37. doi: 10.1007/s12017-013-8248-8. Epub 2013 Jul 30.

PMID:
23896721
10.

Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.

Xifró X, Giralt A, Saavedra A, García-Martínez JM, Díaz-Hernández M, Lucas JJ, Alberch J, Pérez-Navarro E.

Neurobiol Dis. 2009 Dec;36(3):461-9. doi: 10.1016/j.nbd.2009.08.012. Epub 2009 Sep 4.

PMID:
19733666
11.

Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.

Ginés S, Bosch M, Marco S, Gavaldà N, Díaz-Hernández M, Lucas JJ, Canals JM, Alberch J.

Eur J Neurosci. 2006 Feb;23(3):649-58.

PMID:
16487146
12.

Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin.

Her LS, Goldstein LS.

J Neurosci. 2008 Dec 10;28(50):13662-72. doi: 10.1523/JNEUROSCI.4144-08.2008.

13.

Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.

Gharami K, Xie Y, An JJ, Tonegawa S, Xu B.

J Neurochem. 2008 Apr;105(2):369-79. Epub 2007 Dec 12.

14.

Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.

Ermak G, Hench KJ, Chang KT, Sachdev S, Davies KJ.

J Biol Chem. 2009 May 1;284(18):11845-53. doi: 10.1074/jbc.M900639200. Epub 2009 Mar 6.

15.

Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.

Conforti P, Camnasio S, Mutti C, Valenza M, Thompson M, Fossale E, Zeitlin S, MacDonald ME, Zuccato C, Cattaneo E.

Neurobiol Dis. 2013 Feb;50:160-70. doi: 10.1016/j.nbd.2012.10.015. Epub 2012 Oct 23.

PMID:
23089356
16.

Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.

Choudhury KR, Das S, Bhattacharyya NP.

J Proteomics. 2016 Jan 30;132:155-66. doi: 10.1016/j.jprot.2015.11.007. Epub 2015 Nov 12.

PMID:
26581643
17.

Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity.

Xifró X, Anglada-Huguet M, Rué L, Saavedra A, Pérez-Navarro E, Alberch J.

Mol Neurodegener. 2011 Oct 31;6:74. doi: 10.1186/1750-1326-6-74.

18.

Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.

Gratuze M, Noël A, Julien C, Cisbani G, Milot-Rousseau P, Morin F, Dickler M, Goupil C, Bezeau F, Poitras I, Bissonnette S, Whittington RA, Hébert SS, Cicchetti F, Parker JA, Samadi P, Planel E.

Hum Mol Genet. 2015 Jan 1;24(1):86-99. doi: 10.1093/hmg/ddu456. Epub 2014 Sep 8.

PMID:
25205109
19.

Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.

Cho KJ, Lee BI, Cheon SY, Kim HW, Kim HJ, Kim GW.

Neuroscience. 2009 Nov 10;163(4):1128-34. doi: 10.1016/j.neuroscience.2009.07.048. Epub 2009 Jul 28.

PMID:
19646509
20.

PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.

Saavedra A, García-Martínez JM, Xifró X, Giralt A, Torres-Peraza JF, Canals JM, Díaz-Hernández M, Lucas JJ, Alberch J, Pérez-Navarro E.

Cell Death Differ. 2010 Feb;17(2):324-35. doi: 10.1038/cdd.2009.127. Epub 2009 Sep 11.

Supplemental Content

Support Center